FDA Approves Northera for Orthostatic Hypotension In Parkinson’s Patients
Posted Feb 19 2014 6:13pm
From the Michael J. Fox Foundation for Parkinson’s Research Newsletter:
Yesterday the U.S. Food and Drug Administration approved the drug Northera — the brand name for droxidopa — to treat orthostatic hypotension in Parkinson’s patients.
This approval after a lengthy review process is a true victory for people with Parkinson’s experiencing this common and debilitating symptom. Orthostatic hypotension is a sudden drop in blood pressure when standing, which can cause dizziness, falls and injury.
Since taking Northera can raise blood pressure when lying down, users are cautioned to sleep with their head and upper body elevated.
Tomorrow The Michael J. Fox Foundation will host a Webinar on orthostatic hypotension and other symptoms that affect the autonomic nervous system, which controls “automatic” muscle movements such as breathing and heart beat that keep us alive. Join us to hear from expert researchers and ask questions on Thursday, February 20 at 12 p.m. ET.